Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3520 ARTÍCULOS , VIENDO DEL 2131 AL 2145

Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis

Yadav S, Dixit A, Agrawal S, Singh A, Srivastava G, Singh AK, Srivastava PK, Prakash O, Singh MP.

Mol Neurobiol. 2012 Oct;46(2):495-512. doi: 10.1007/s12035-012-8291-8. Epub 2012 Jun 27.

Fronto-striatal dysfunction in type 3 familial cortical myoclonic tremor epilepsy occurring during aging

Magnin E, Vidailhet M, Ryff I, Ferreira S, Labauge P, Rumbach L.

J Neurol. 2012 Dec;259(12):2714-9. doi: 10.1007/s00415-012-6575-6. Epub 2012 Jun 27.

Neurochemistry and the non-motor aspects of PD

Ferrer I, López-Gonzalez I, Carmona M, Dalfó E, Pujol A, Martínez A.

Neurobiol Dis. 2012 Jun;46(3):508-26. doi: 10.1016/j.nbd.2011.10.019.

Molecular rotors: what lies behind the high sensitivity of the thioflavin-T fluorescent marker

Amdursky N, Erez Y, Huppert D.

Acc Chem Res. 2012 Sep 18;45(9):1548-57. doi: 10.1021/ar300053p. Epub 2012 Jun 27.

[Radiofrequency ablation of a left free-wall accessory pathway by transradial approach]

Ibarra-Castillo R, Amores-Arellano N.

Arch Cardiol Mex. 2012 Apr-Jun;82(2):131-4.

Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis

Dunkel P, Chai CL, Sperlágh B, Huleatt PB, Mátyus P.

Expert Opin Investig Drugs. 2012 Sep;21(9):1267-308. doi: 10.1517/13543784.2012.703178. Epub 2012 Jun 28.

The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases

Joshi G, Johnson JA.

Recent Pat CNS Drug Discov. 2012 Dec;7(3):218-29. doi: 10.2174/157488912803252023.

Curcuminoids in neurodegenerative diseases

Kim DS, Kim JY, Han Y.

Recent Pat CNS Drug Discov. 2012 Dec;7(3):184-204. doi: 10.2174/157488912803252032.

Biopsychosocial and spiritual aspects of Parkinson disease: an integrative review

Hermanns M, Deal B, Haas B.

J Neurosci Nurs. 2012 Aug;44(4):194-205. doi: 10.1097/JNN.0b013e3182527593.

[Gastrointestinal dysfunction in idiopathic Parkinson's disease]

Del Tredici K, Jost WH.

Nervenarzt. 2012 Oct;83(10):1282-91. doi: 10.1007/s00115-012-3575-9.

Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)

Lewitt PA, Hauser RA, Lu M, Nicholas AP, Weiner W, Coppard N, Leinonen M, Savola JM.

Neurology. 2012 Jul 10;79(2):163-9. doi: 10.1212/WNL.0b013e31825f0451. Epub 2012 Jun 27.

Environmental risk factors for REM sleep behavior disorder: a multicenter case-control study

Postuma RB, Montplaisir JY, Pelletier A, Dauvilliers Y, Oertel W, Iranzo A, Ferini-Strambi L, Arnulf I, Hogl B, Manni R, Miyamoto T, Mayer G, Stiasny-Kolster K, Puligheddu M, Ju Y, Jennum P, Sonka K, Santamaria J, Fantini ML, Zucconi M, Leu-Semenescu S, Frauscher B, Terzaghi M, Miyamoto M, Unger MM, Cochen De Cock V, Wolfson C.

Neurology. 2012 Jul 31;79(5):428-34. doi: 10.1212/WNL.0b013e31825dd383. Epub 2012 Jun 27.

Protein degradation pathways in Parkinson's disease: curse or blessing

Ebrahimi-Fakhari D, Wahlster L, McLean PJ.

Acta Neuropathol. 2012 Aug;124(2):153-72. doi: 10.1007/s00401-012-1004-6. Epub 2012 Jun 29.

Gene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced delivery

Miranpuri GS, Kumbier L, Hinchman A, Schomberg D, Wang A, Marshall H, Kubota K, Ross C, Sillay K.

Ann Neurosci. 2012 Jul;19(3):133-46. doi: 10.5214/ans.0972.7531.190310.

Vascular Parkinsonism and cognitive impairment: literature review, Brazilian studies and case vignettes

Vale TC, Barbosa MT, Caramelli P, Cardoso F.

Dement Neuropsychol. 2012 Jul-Sep;6(3):137-144. doi: 10.1590/S1980-57642012DN06030005.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias